Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus chemotherapy in advanced pancreatic ductal adenocarcinoma
NCT05149326Phase 3Active, not recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erfonrilimab in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Alphamab Oncology. Primary endpoint: Overall Survival up to 2 years. Started Jan 2022; status: active, not recruiting.
02
Drugs
erfonrilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05149326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149326.